Drugs / EOC237
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05895825 | Jul 2023 → Apr 2026 overdue | neoplasm | Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EOC237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05895825 ↗ |
| Route | Oral | “EOC237 was taken orally under fasted conditions” NCT05895825 ↗ |